The strongest therapeutic case in the literature — and still more modest than the marketing.
The 2017 National Academies review rated the evidence for chronic pain in adults "substantial", its highest tier. But average effect sizes are small: many patients try cannabis-based products, a minority report meaningful relief.
NASEM 2017 — The Health Effects of Cannabis ↗Diabetic neuropathy, post-herpetic neuralgia and MS-related pain show the most repeatable response in trials — which is where approved cannabinoid medicines aim their indications.
Cannabinoids & neuropathic pain — PubMed ↗Observational studies show some patients reduce opioid use alongside cannabis, and some jurisdictions show lower opioid prescribing after legalization. But observational data cannot prove cause: no randomized trial has demonstrated opioid-sparing.
Cannabis & opioid substitution — PubMed ↗Cannabis use disorder develops in roughly 1 in 10 users overall, and more with daily use. When use is daily and open-ended, that trade-off deserves to be discussed explicitly with a physician.
Cannabis use disorder prevalence — PubMed ↗The landmark 2017 National Academies report — the most rigorous evidence review to date — found substantial evidence for only three indications: chronic pain in adults, chemotherapy-induced nausea (oral cannabinoids), and MS-related spasticity. Nearly everything else sits at "limited" or "insufficient."
Medical Evidence MIXED / UNSETTLEDSome state-level studies found fewer opioid prescriptions and overdoses after legalization; later re-analyses with more states and years found the effect reversed or vanished. Individual patients report real substitution benefits; population evidence is unstable. An open, important question.
Medical Evidence STRONG EVIDENCEDronabinol and nabilone (synthetic THC) are approved for chemo nausea and AIDS wasting; nabiximols (THC+CBD spray) is approved for MS spasticity in 25+ countries; Epidiolex (CBD) for severe epilepsy. The medical channel exists and works — it is simply narrower than the dispensary menu suggests.
Medical Evidence STRONG EVIDENCEWhile CB1 dominates the brain, CB2 receptors concentrate in immune cells and peripheral tissues, modulating inflammation. CB2 is the main reason researchers believe cannabinoids could have anti-inflammatory effects without a high.
The Endocannabinoid SystemCannabis is not an approved treatment for chronic pain in most jurisdictions, and nothing here recommends using it. If chronic pain affects your life, bring this research — literally, these sources — to a physician and decide together. Laws differ by country and state; check CannabisLaws.ai before anything else.